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OBJECTIVE—The liver plays a critical role in integrating and
controlling glucose metabolism. Thus, it is important that the
liver receive and react to signals from other tissues regarding the
nutrient status of the body. Leptin, which is produced and
secreted from adipose tissue, is a hormone that relays informa-
tion regarding the status of adipose depots to other parts of the
body. Leptin has a profound inﬂuence on glucose metabolism, so
we sought to determine if leptin may exert this effect in part
through the liver.
RESEARCH DESIGN AND METHODS—To explore this pos-
sibility, we created mice that have disrupted hepatic leptin
signaling using a Cre-lox approach and then investigated aspects
of glucose metabolism in these animals.
RESULTS—The loss of hepatic leptin signaling did not alter
body weight, body composition, or blood glucose levels in the
mild fasting or random-fed state. However, mice with ablated
hepatic leptin signaling had increased lipid accumulation in the
liver. Further, as male mice aged or were fed a high-fat diet, the
loss of hepatic leptin signaling protected the mice from glucose
intolerance. Moreover, the mice displayed increased liver insulin
sensitivity and a trend toward enhanced glucose-stimulated
plasma insulin levels. Consistent with increased insulin sensitiv-
ity, mice with ablated hepatic leptin signaling had increased
insulin-stimulated phosphorylation of Akt in the liver.
CONCLUSIONS—These data reveal that unlike a complete
deﬁciency of leptin action, which results in impaired glucose
homeostasis, disruption of leptin action in the liver alone in-
creases hepatic insulin sensitivity and protects against age- and
diet-related glucose intolerance. Thus, leptin appears to act as a
negative regulator of insulin action in the liver. Diabetes 59:
3032–3040, 2010
I
t is well-established that there is a link between
diabetes and obesity; however, the molecular mech-
anisms behind this association are not fully under-
stood. A potential factor linking diabetes and obesity
is the hormone leptin. Leptin is a hormone produced
predominantly in adipocytes (1) and is typically present in
the circulation at levels proportional to fat mass (2). Mice
that lack functional leptin (ob/ob) or leptin receptors
(db/db) are obese and have a phenotype similar to type 2
diabetes (3).
Although it is often assumed that the diabetic phenotype
of these mice is a result of their obesity, the two pheno-
types are in fact at least partially independent and several
key observations clearly highlight this. In ob/ob and db/db
mice, hyperinsulinemia, and thus the disruption of normal
glucose homeostasis, precedes changes in body mass
(4,5). Doses of recombinant leptin that do not inﬂuence
body weight are able to normalize glucose levels and
reduce the hyperinsulinemia of ob/ob mice with minimal
changes in body weight (6,7). Further evidence that leptin
has direct effects on glucose metabolism comes from the
rare condition of severe lipodystrophy, the near complete
loss of adipose mass. Paradoxically, similar to too much
fat, too little fat caused by lipodystrophy is associated with
a type 2 diabetic phenotype (8) and leptin therapy dramat-
ically ameliorates diabetes in this situation (9). Collec-
tively, these observations indicate that leptin has powerful
actions on glucose homeostasis, independent of its well-
described central actions on food intake and energy
expenditure (10).
Several studies have shown that the weight-independent
actions of leptin on glucose metabolism result from acti-
vation of central leptin signaling pathways (11–13) that
regulate hepatic glucose ﬂux (12,13). Interestingly, leptin
receptor transcripts are also expressed in the liver itself
(14), including the long signaling isoform, leptin receptor b
(Lepr-b) (15–17), and many studies reveal that leptin also
has direct action on hepatocytes (17–19). To directly
evaluate the contribution of hepatic leptin signaling on
aspects of metabolism, Cohen et al. (20) used a Cre-lox
approach to allow hepatocyte-speciﬁc deletion of the
entire leptin receptor. The investigators found that hepa-
tocyte-speciﬁc ablation of leptin receptors did not alter
body weight, body composition, or free-feeding levels of
glucose or insulin (20). We sought to further these studies
by investigating metabolism at several different ages, on a
high-fat diet, and under the setting of a glucose challenge.
For these studies, we too employed a Cre-lox approach.
However, distinct from that of the Cohen study, we
generated mice with hepatocyte-speciﬁc ablation of leptin
signaling domains as opposed to ablation of the complete
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hepatic leptin signaling does not impact many parameters
of glucose metabolism and body composition. Interest-
ingly, however, we discovered that a loss of hepatic leptin
signaling protects mice from age- and diet-related glucose
intolerance. This protection from glucose intolerance cor-
relates with elevated glucose-stimulated plasma insulin
levels, increased liver insulin sensitivity, and increased
hepatic lipid accumulation. Collectively, our data reveal a
previously unappreciated role for hepatic leptin signaling
in regulating glucose homeostasis.
RESEARCH DESIGN AND METHODS
Mice. C57BL/6, db/db and C57BL/6-Tg(Alb-cre)21Mgn (referred to as Albcre
tg
) were obtained from The Jackson Laboratory (Bar Harbor, ME).
Lepr
ﬂox/ﬂox Albcre tg
 mice, which lack hepatic leptin signaling, and their
Lepr
ﬂox/ﬂox Albcre tg
 littermate controls were generated as described in the
supplementary information, available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db10-0074/DC1. All procedures with ani-
mals were approved by the University of British Columbia Animal Care
Committee and carried out in accordance with the Canadian Council on
Animal Care guidelines. For additional details, see the supplementary
information.
PCR and RT-PCR analysis. Genomic DNA was prepared with DNeasy kits
(Qiagen, Mississauga, Canada). Brain tissue was prepared as a homogenate of
the brain minus the hypothalamus. For RNA extractions, the liver was excised
and immediately placed in RNAlater (Qiagen). Tissue was homogenized with
an Ultra-Turrax and puriﬁed using an RNeasy kit (Qiagen). Reverse transcript
reactions were performed with a poly T primer using a Superscript First-
Strand Synthesis kit (Invitrogen, Burlington, Canada). The generated cDNA
was then used for PCR. Primer sequences are available in the supplementary
information.
Measurement of lean to lipid mass. Measurements were performed with a
Bruker BioSpec 70/30 7 Tesla magnetic resonance imaging (MRI) scanner
(Bruker Biospin, Ettlingen, Germany). The ratio of lean/fat tissue is expressed
as weight/weight and was calculated from the nuclear magnetic resonance
(NMR) data as described (21). For additional details, see the supplementary
information.
Measurement of hepatic lipid content. Hepatic triglycerides and choles-
terol were measured by a modiﬁed protocol of Briaud et al. (22). For
additional details, see the supplementary information.
Plasma analyte analysis. Body weight, blood glucose, and insulin were
typically measured following a 4-h fast unless speciﬁed otherwise. Blood
glucose concentration was measured with a OneTouch Ultra Glucometer
(LifeScan, Burnaby, Canada) from the saphenous vein. Plasma insulin levels
were measured by an Insulin Mouse Ultrasensitive enzyme-linked immunosor-
bent assay (ELISA) (ALPCO Diagnostics, Salem, NH), and plasma leptin levels
were determined using a mouse leptin ELISA (Crystal Chem, Downers Grove,
IL).
In vivo oral glucose tolerance, glucose-stimulated insulin levels, and
insulin tolerance tests. Mice were fasted for 4 h and then given either an
oral glucose gavage (1.5 mg of glucose per g body weight unless otherwise
speciﬁed) of a 30% glucose solution or an intraperitoneal injection of 0.75
units/kg (females) or 1.0 units/kg (males) human synthetic insulin (Novolin ge
Toronto, Novo Nordisk, Mississauga, Canada). Blood was sampled from the
saphenous vein and measured for glucose or insulin as described above.
Measurements of -cell mass. Pancreata were removed and ﬁxed in 4%
paraformaldehyde overnight at 4°C and then stored in 70% ethanol prior to
embedding in parafﬁn and sectioning. For each mouse, insulin-positive area
was assessed on three pancreas sections separated by 35 m. Details
regarding processing, staining, and quantiﬁcation of -cell mass are available
in the supplementary information.
Hyperinsulinemic-euglycemic clamps. Hyperinsulinemic-euglycemic clamps
were performed as previously described (23). For a brief description, see the
supplementary information.
Western blot analysis. Liver samples were collected immediately after the
hyperinsulinemic-euglycemic clamp. Western blots were performed using
antibodies against phosphorylated Akt (#4060; Cell Signaling Technologies,
Danvers, MA) and total Akt (#9272; Cell Signaling Technologies). See the
supplementary information for additional details.
Statistical analysis. Data are represented as means  SEM, and signiﬁcance
was set at P  0.05. Analyses were done by Student’s t tests.
RESULTS
Generation of mice with hepatocyte-speciﬁc disrup-
tion of leptin receptor signaling. To generate mice with
hepatocyte-speciﬁc disruption of leptin signaling, we uti-
lized Lepr
ﬂox/ﬂox mice, which have loxP sites ﬂanking exon
17 of the leptin receptor gene (Lepr) (24,25). Exon 17 of
Lepr is present in the long signaling isoform of Lepr-b and
encodes the Janus kinase (JAK) binding site. Upon Cre-
mediated recombination at the loxP sites, exon 17 is
excised (herein referred to as Lepr
17), and a resulting
frame shift mutation generates an altered 3 terminus (25)
that no longer encodes tyrosine 985 and tyrosine 1138,
which are sites of JAK-mediated tyrosine phosphorylation
(26). Mice homozygous for the Lepr
17 allele are deﬁcient
in leptin-stimulated STAT phosphorylation (27,28). The
Lepr
ﬂox/ﬂox mice were crossed with Albcre tg
 mice, which
have the cre transgene under the control of the albumin
promoter, conferring hepatocyte-speciﬁc expression of
Cre (29). The resulting Lepr
ﬂox/wt mice with and without
the Albcre transgene were bred to generate Lepr
ﬂox/ﬂox
Albcre tg
 and Lepr
ﬂox/ﬂox Albcre tg
 mice.
Following generation of Lepr
ﬂox/ﬂox Albcre tg
 and
Lepr
ﬂox/ﬂox Albcre tg
 littermate controls, we investigated
the extent and speciﬁcity of Cre-mediated excision of exon
17 of the leptin receptor. In all tissues tested, there was a
PCR product of 1,370 bp, which corresponds to the
expected product size of the Lepr
ﬂox allele (Fig. 1A).
Although present, there was very little of this amplicon
generated from liver DNA of Lepr
ﬂox/ﬂox Albcre tg
 mice,
likely contributed by non-hepatocytes. Instead, the major
product ampliﬁed from liver DNA of Lepr
ﬂox/ﬂox Albcre tg

mice was 950 bp in size, which corresponds to the
expected size of the Lepr
ﬂox allele following Cre-mediated
excision (resulting in Lepr
17). Thus, it appears that in the
Lepr
ﬂox/ﬂox Albcre tg
 mice, excision at the Lepr
ﬂox allele
among the tissues tested was restricted to the liver and
that the majority of hepatocytes carry the Lepr
17 rather
than the Lepr
ﬂox allele. Consistent with this, an analysis of
Lepr-b mRNA transcripts by RT-PCR revealed that while
the only ampliﬁed product detected from the liver of
Lepr
ﬂox/ﬂox Albcre tg
 mice corresponded to the antici-
pated 343 bp product from the wild-type Lepr-b transcript,
in the liver of the Lepr
ﬂox/ﬂox Albcre tg
 mice, only an
amplicon of the predicted size of the Lepr
17 transcript
was detected (Fig. 1B). The Lepr
17 transcript has been
previously shown to result in impaired leptin-stimulated
JAK/STAT signaling in mouse lines derived from the same
Lepr
ﬂox/ﬂox mice used in our study (24,28). Thus, our mice,
which we have shown to predominantly express the
Lepr
17 allele speciﬁcally in the liver, must have impaired
leptin-stimulated hepatic JAK/STAT activation.
Loss of hepatic leptin signaling does not substan-
tially alter body weight or body composition. To
characterize the physiological effect of ablated hepatic
leptin signaling, we ﬁrst assessed body weight and com-
position. Unlike mice with a complete loss of leptin
signaling (db/db mice), which are much heavier than
control mice (C57BL/6), the loss of hepatic leptin signaling
did not substantially alter body weight relative to controls
in either sex at the various ages tested (Table 1). To assess
body composition, the total lean-to-lipid mass ratio of
Lepr
ﬂox/ﬂox Albcre tg
 and Lepr
ﬂox/ﬂox Albcre tg
 littermate
controls was assessed at 6 and 16 weeks of age by NMR. At
both ages and in each sex, there was a similar ratio of
lean-to-lipid mass in mice with and without hepatic leptin
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lacking leptin signaling in the liver had 16% more triglyc-
erides and 48% more cholesterol in their livers when
compared with littermate controls (Fig. 2E and F). Thus,
while a loss of hepatic leptin signaling does not alter body
weight or adiposity, it does result in increased lipid
accumulation in the liver.
Loss of hepatic leptin signaling does not have a major
inﬂuence on basal metabolic parameters. We next
sought to determine how a loss of hepatic leptin signaling
might affect basal metabolic parameters. Plasma leptin
levels were not signiﬁcantly different between groups in
either sex at 18 weeks of age (5.66  1.11 ng/ml vs. 4.36 
2.63 ng/ml for male Lepr
ﬂox/ﬂox Albcre tg
 vs. Lepr
ﬂox/ﬂox
Albcre tg
, P 	 0.308, n  4 and 4.11  0.78 ng/ml vs.
6.80  1.64 ng/ml for female Lepr
ﬂox/ﬂox Albcre tg
 vs.
Lepr
ﬂox/ﬂox Albcre tg
, P 	 0.123, n  3). Similarly, plasma
leptin binding protein levels also appeared to be un-
changed between Lepr
ﬂox/ﬂox Albcre tg
 and littermate
controls (supplementary Fig. 1). Further, plasma lipid
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FIG. 1. Lepr
ﬂox/ﬂox Albcre tg
 mice have a liver-speciﬁc loss of the leptin receptor signaling domain. A: Genomic DNA from tissues of Lepr
ﬂox/ﬂox
mice with and without the Albcre transgene was used as template for PCR of the Lepr
ﬂox allele. The predicted product sizes are 1,369 bp for
Lepr
ﬂox and 952 bp for Lepr
17. B: RNA was extracted from the livers of Lepr
ﬂox/ﬂox mice and used as template for RT-PCR with primers ﬂanking
exon 17. The predicted product sizes are 343 bp for Lepr
ﬂox and 267 bp for Lepr
17 transcripts. Arrows to the left mark the migration of molecular
weight markers in bp.
TABLE 1
Metabolic parameters of mice with and without hepatic leptin signaling
Metabolic parameter
Body weight
(g)
Fasting
a
glucose (mM)
Random-fed
b
glucose (mM)
Fasting
a insulin
(ng/ml)
6 weeks  Lepr
ﬂox/ﬂox Albcre tg
 25.7  0.5 (22) 9.7  0.3 (22) 8.3  0.4 (7) 1.17  0.13 (5)
Lepr
ﬂox/ﬂox Albcre tg
 25.6  0.5 (24) 9.3  0.3 (24) 7.6  0.3 (8) 1.09  0.11 (5)
C57BL/6 20.5  0.5 (8) 11.1  0.3 (16) 9.0  0.4 (8) 0.86  0.06 (8)
db/db 30.0  0.7 (8)* 15.1  1.8 (8)* 28.1  1.6 (8)* 7.89  0.91 (8)*
 Lepr
ﬂox/ﬂox Albcre tg
 20.5  0.3 (18) 8.3  0.3 (18) 7.3  0.3 (8) 0.53  0.15 (6)
Lepr
ﬂox/ﬂox Albcre tg
 19.7  0.3 (17) 8.5  0.3 (16) 7.2  0.2 (5) 0.34  0.05 (3)
C57BL/6 16.0  0.4 (8) 8.0  0.3 (8) 8.1  0.4 (8) 0.53  0.09 (4)
db/db 31.6  0.5 (8)* 22.1  1.6 (8)* 28.9  0.5 (8)* 10.18  1.38 (7)*
12 weeks  Lepr
ﬂox/ﬂox Albcre tg
 34.0  0.9 (29) 10.1  0.3 (29) 8.3  0.4 (6) 1.38  0.30 (6)
Lepr
ﬂox/ﬂox Albcre tg
 32.6  0.9 (35) 9.9  0.3 (35) 8.0  0.3 (7) 1.32  0.29 (7)
C57BL/6 28.8  1.0 (14) 11.1  0.4 (14) 9.0  0.2 (8) 2.61  0.76 (8)
db/db 50.5  0.9 (8)* 28.0  1.0 (8)* 28.1  1.1 (8)* 11.2  2.2 (8)*
 Lepr
ﬂox/ﬂox Albcre tg
 22.2  0.9 (27) 7.9  0.3 (27) 8.0  0.3 (5) 0.54  0.10 (5)
Lepr
ﬂox/ﬂox Albcre tg
 23.1  0.5 (22) 7.7  0.2 (22) 8.0  0.2 (5) 0.48  0.17 (5)
C57BL/6 18.7  0.6 (8) 7.2  0.4 (8) 7.0  0.1 (8) 0.49  0.06 (8)
db/db 51.7  0.6 (8)* 28.1  2.2 (8)* 24.8  2.4 (8)* 7.46  0.76 (8)*
16 weeks  Lepr
ﬂox/ﬂox Albcre tg
 41.6  1.1 (24) 10.9  0.5 (24) 7.8  0.4 (5) 2.00  0.41 (18)
Lepr
ﬂox/ﬂox Albcre tg
 39.1  1.1 (25) 10.6  0.3 (26) 8.6  0.5 (7) 1.70  0.25 (23)
C57BL/6 31.7  1.0 (14) 9.7  0.3 (14) 8.2  0.5 (8) 2.32  0.77 (8)
db/db 56.7  0.9 (8)* 25.6  2.8 (8)* 25.1  1.8 (8)* 12.0  2.10 (8)*
 Lepr
ﬂox/ﬂox Albcre tg 26.9  1.2 (12) 7.5  0.4 (12) 7.5  0.3 (5) 0.82  0.20 (4)
Lepr
ﬂox/ﬂox Albcre tg
 25.4  1.0 (8) 7.2  0.2 (8) 7.3  0.3 (5) 0.41  0.01 (4)*
C57BL/6 20.4  0.7 (8) 8.4  0.5 (8) 7.5  0.2 (8) 0.37  0.06 (8)
db/db 57.9  0.6 (8)* 21.7  2.5 (8)* 21.0  2.8 (8)* 9.67  1.42 (6)*
aMice were fasted for 4 h during the light cycle.
bSamples were collected between 11:00 p.m.–1:00 a.m. *P  0.05 vs. control (Lepr
ﬂox/ﬂox
Albcre tg
 or C57BL/6).
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ﬂox/ﬂox
Albcre tg
 and their littermate controls at 6, 12, and 16
weeks of age (supplementary Table 1). We also measured
insulin and blood glucose levels in Lepr
ﬂox/ﬂox Albcre tg

and Lepr
ﬂox/ﬂox Albcre tg
 littermate controls in both the
4-h fasted state as well as the fed state during the light and
dark phases, respectively. For comparison, we also mea-
sured these parameters in mice lacking functional leptin
receptors in all tissues (db/db) and the relevant wild-type
controls (C57BL/6). The complete loss of leptin action in
the db/db mice resulted in increased body mass, hypergly-
cemia (in both the fasted and fed state) and fasting
hyperinsulinemia in both genders at 6, 12, and 16 weeks of
age (Table 1). In contrast, a liver-speciﬁc loss of leptin
signaling did not signiﬁcantly alter blood glucose levels (in
either fasted or random-fed state) of either sex at any of
the ages investigated. Consistent with this, we found no
alterations in hepatic PEPCK and glucose-6-phosphatase
(G6Pase) transcript levels between male Lepr
ﬂox/ﬂox Albcre
tg
 and tg
 littermate controls after a 4-h fast (supplemen-
tary Fig. 2A). Further, pyruvate-induced gluconeogenesis
after an overnight fast was similar in male Lepr
ﬂox/ﬂox
Albcre tg
 mice and their littermate controls (supplemen-
tary Fig. 2B). Fasting plasma insulin levels in males with
hepatocyte-speciﬁc ablation of leptin signaling were also
similar to levels in littermate controls. However, the
Lepr
ﬂox/ﬂox Albcre tg
 females had lower fasting plasma
insulin levels compared with their littermate controls at all
ages measured, and this difference was statistically signif-
icant at 16 weeks of age (P 	 0.042).
Loss of hepatic leptin signaling protects against age-
and diet-related glucose intolerance. To assess if the
response to a nutritional challenge may be altered by a
loss of hepatic leptin signaling, oral glucose tolerance tests
(OGTTs) were performed on Lepr
ﬂox/ﬂox Albcre tg
 and
Lepr
ﬂox/ﬂox Albcre tg
 littermate controls at several differ-
ent ages, along with db/db and C57BL/6 wild-type controls.
As expected, the complete absence of leptin signaling in
the male db/db mice resulted in striking glucose intoler-
ance in young 6-week-old mice (Fig. 3F). Surprisingly, in
contrast to the db/db mice, the 6-week-old male mice
lacking hepatic leptin signaling had a trend toward slightly
improved glucose tolerance (Fig. 3A). This trend became
more prominent as the mice aged and the differences in
the peak blood glucose values were statistically signiﬁcant
in 16-week-old mice and beyond (Figs. 3B–D). At 16 and 42
weeks old, the Lepr
ﬂox/ﬂox Albcre tg
 mice had an 18%
improvement in glucose excursion relative to the litter-
mate controls as measured by area under the curve (AUC)
analysis. Interestingly, we did not see such a difference in
females when comparing the Lepr
ﬂox/ﬂox Albcre tg
 mice
and their littermate controls at the same ages as the males
(supplementary Fig. 3). Since it appeared that male mice
lacking hepatic leptin signaling were protected from an
age-related deterioration of glucose tolerance, we tested if
this protection would persist when fed a high-fat diet.
Lepr
ﬂox/ﬂox Albcre tg
 and their littermate controls were
fed a high-fat diet for 20 weeks starting at 4 weeks of age,
and OGTTs were performed. Similar to the chow-fed mice,
the high-fat–fed male mice lacking hepatic leptin signaling
had improved glucose tolerance relative to littermate
controls (Fig. 3E) despite no differences in body weight
(55.9  4.0 g for Lepr
ﬂox/ﬂox Albcre tg
 and 54.3  2.6 g for
Lepr
ﬂox/ﬂox Albcre tg
, P 	 0.365, n  6). The magnitude of
this improvement in glucose tolerance was greater in
high-fat–fed mice than the chow-fed mice, as there was a
40% improved glucose excursion (by AUC analysis) in
mice lacking hepatic leptin signaling. Thus, the loss of
hepatic leptin signaling allows mice to retain normal
glucose tolerance as they age even when on a high-fat diet.
Since it has been reported that a cre transgene, the
RIPcre transgene, itself can cause glucose intolerance
(30), we investigated if the differences in glucose tolerance
in our studies were a direct result of excision of lepr exon
17 or possibly the presence of the Albcre transgene. To test
this, we performed OGTTs in male Lepr
ﬂox/wt Albcre tg

and their littermate controls at 16 weeks of age. Glucose
excursion was very similar between the two groups of
mice when analyzed by AUC analysis (Lepr
ﬂox/wt Albcre
tg
 1,570  140 vs. Lepr
ﬂox/wt Albcre tg
 1,556  220 and
P 	 0.480, n  7). This reveals that the presence of the cre
transgene itself is not the cause of the altered glucose
tolerance (Fig. 3) but rather the loss of leptin signaling in
hepatocytes, and that the phenotype is only present when
both copies of the leptin receptor allele are disrupted.
Increased glucose-stimulated plasma insulin levels
and increased insulin sensitivity contribute to im-
proved glucose tolerance in mice lacking hepatic
leptin signaling. To explore the potential mechanism of
improved glucose tolerance in the Lepr
ﬂox/ﬂox Albcre tg

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FIG. 2. Attenuation of hepatic leptin signaling does not alter body
composition. A and C: Lepr
ﬂox/ﬂox Albcre tg
 mice and littermate
controls were assessed for body weight as well as (B and D) body
composition as measured by NMR at 6 and 16 weeks old. At 6 weeks old,
n > 7, and at 16 weeks old, n > 5, for Lepr
ﬂox/ﬂox Albcre tg
 and
littermate controls. E and F: Twenty-one-week-old male mice were
fasted for 4 h and then the liver was harvested. Lipids were isolated by
a chloroform:methanol extraction and reconstituted into Thesit mi-
celles. Samples were then assayed for triglycerides and cholesterol,
n > 8 in each group. Data are mean  SEM.
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with and without hepatic leptin signaling. As seen in Fig.
4A, following a glucose gavage, the Lepr
ﬂox/ﬂox Albcre tg

mice had 1.35-fold increase in plasma insulin relative to
the Lepr
ﬂox/ﬂox Albcre tg
 littermate controls (AUC of
252  33 and 186  31, respectively, P 	 0.053, n  13).
This increase was not associated with an increase in -cell
mass (Figs. 4B and C). Similarly, a trend for increased
glucose-stimulated insulin levels was also seen in
Lepr
ﬂox/ﬂox Albcre tg
 mice on a high-fat diet (supplemen-
tary Fig. 4).
While the increased plasma insulin following a glucose
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FIG. 3. Loss of hepatic leptin signaling prevents age- and diet-related glucose intolerance. Oral glucose tolerance tests were performed on male
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FIG. 4. Attenuation of hepatic leptin signaling increases glucose-stimulated insulin levels. A: Plasma insulin levels were monitored following a
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erance in mice lacking hepatic leptin signaling, we wanted
to determine if insulin sensitivity may also contribute to
this phenotype. To assess whole-body insulin sensitivity,
insulin tolerance tests were performed in male and female
mice at 19 weeks of age. The Lepr
ﬂox/ﬂox Albcre tg

females displayed increased insulin sensitivity compared
with the Lepr
ﬂox/ﬂox Albcre tg
 controls (Fig. 5A), while
there was no difference in whole-body insulin sensitivity in
the male mice (Fig. 5B).
To more speciﬁcally explore insulin sensitivity at the
level of the liver in male mice, hyperinsulinemic-euglyce-
mic clamp studies were performed. Figure 6A and B shows
that hyperinsulinemia was achieved while maintaining
euglycemia during the clamp, and that no differences in
blood glucose or plasma insulin levels were observed
between Lepr
ﬂox/ﬂox Albcre tg
 and their Lepr
ﬂox/ﬂox Albcre
tg
 littermate controls. In the basal (non-hyperinsulinemic)
state, whole-body glucose utilization and endogenous glu-
cose production were similar for the Lepr
ﬂox/ﬂox Albcre tg

and Lepr
ﬂox/ﬂox Albcre tg
 littermate controls (Fig. 6C). As
expected, in both Lepr
ﬂox/ﬂox Albcre tg
 and Lepr
ﬂox/ﬂox
Albcre tg
 mice, glucose utilization increased and endog-
enous glucose production decreased in the hyperinsuline-
mic phase. While whole-body glucose utilization was
similar between the mice with and without hepatic leptin
signaling, there was a signiﬁcant difference in insulin-
induced suppression of endogenous glucose production
(P 	 0.03). In the littermate controls, insulin suppressed
glucose production by 39%, while in the Lepr
ﬂox/ﬂox Albcre
tg
 mice, insulin suppressed glucose production by 68%.
Since the majority of endogenously produced glucose
comes from hepatocytes, these data provide evidence that
a loss of hepatic leptin signaling mediates enhanced
insulin sensitivity in the liver. This notion is supported by
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mediator of insulin signaling, was increased in mice lack-
ing hepatic leptin signaling when compared with littermate
controls (Fig. 7). Taken together, our data suggest that a
loss of hepatic leptin signaling leads to increased insulin
sensitivity in the liver.
DISCUSSION
These studies reveal new insights into the role of leptin
signaling in the liver. First, we have shown that our mice
lacking the leptin receptor signaling domain in the liver
have increased hepatic lipid accumulation. This is consis-
tent with the potent lipolytic effects of leptin: db/db mice
have substantial hepatic steatosis, and the re-expression
of leptin receptors in the livers of leptin receptor-deﬁcient
Zucker rats reduces hepatic steatosis (31). Further, our
data show that mice lacking hepatic leptin signaling have
increased insulin sensitivity in the liver, which given that
insulin is a potent promoter of lipogenesis (32) and a
suppressor of lipid export from the liver (33), would be
expected to contribute to increased hepatic lipid levels. In
contrast to our ﬁndings, Cohen et al. (20) reported that
mice with a lack of the complete leptin receptor in the
liver have normal hepatic lipid levels. While our mouse
model lacked the leptin receptor signaling domain in the
liver but maintained the extracellular and transmembrane
domains, mice studied by Cohen et al. had a knockout of
the complete receptor. Thus, there may be a role for the
extracellular and transmembrane domains of the leptin
receptor in liver lipid metabolism. However, we also note
that Cohen et al. used different methods to assess hepatic
lipid levels, including possibly using mice of different age
than in our study (age was unspeciﬁed by Cohen et al.) and
using mice heterozygous for the ﬂoxed leptin receptor
gene as controls. These differences in methods could
potentially explain the differences in hepatic lipid content
seen by us and by Cohen et al. since mice heterozygous for
the leptin receptor (db/) or the leptin gene (ob/) have
been shown to have changes in metabolism when com-
pared with wild-type mice (34), with some changes in ob/
mice being age-related (35). Under the conditions that we
measured hepatic lipid levels, mice with an ablation of the
hepatic leptin receptor signaling domain have an increase
in hepatic triglyceride and cholesterol levels when com-
pared with littermate controls, suggesting that the ability
of leptin to ameliorate hepatic steatosis in rodent models
of type 2 diabetes (31) and lipodystrophy (36) may be
mediated, in part, through leptin signaling at the level of
the liver.
Similar to the work of Cohen et al. (20), we ﬁnd that the
loss of hepatic leptin signaling does not have a major
inﬂuence on glucose metabolism in the mildly fasting or
random-fed state. However, we have extended the work of
Cohen et al. to reveal that leptin action on the liver does
inﬂuence glucose metabolism under certain metabolic
stressors. Speciﬁcally, as male mice aged, those lacking
leptin signaling in the liver performed substantially better
during a glucose challenge, remarkably even when fed a
high-fat diet. This improved glucose tolerance was likely
related to increased hepatic insulin sensitivity in 16- to
20-week-old mice and a trend toward increased glucose-
stimulated plasma insulin levels perhaps caused by
changes in interorgan communication between the liver
and the pancreas, which has been demonstrated by several
studies (7,37,38). Taken together, our data show that aged
mice lacking hepatic leptin signaling appear to beneﬁt
from the combined effect of increased hepatic insulin
sensitivity and increased glucose-stimulated insulin levels,
resulting in markedly improved glucose tolerance.
Although we did see an improvement in insulin sensi-
tivity as well as reduced fasting insulin levels in female
mice lacking hepatic leptin signaling compared with con-
trols, this did not manifest in differences in glucose
clearance during an oral glucose challenge. We speculate
that this relates to the better insulin sensitivity and glucose
tolerance in general of female mice relative to their male
counterparts. Since the female controls did not develop
glucose intolerance during the time frame we examined,
we did not see an improvement in glucose tolerance in
female mice lacking hepatic leptin signaling despite the
improved insulin sensitivity.
Many studies have investigated the effect of leptin on
insulin sensitivity; however there is no clear consensus in
the literature if leptin has pro- or anti-insulin sensitizing
effects on the liver (39). In agreement with our current
data, several other studies have found that leptin can
attenuate insulin-induced activities in the liver (17,40).
Other studies reveal that leptin can increase insulin-
mediated actions in the liver (41–43). Consistent with
leptin mediating both pro- and anti-insulin sensitizing
effects, we have observed leptin to increase insulin recep-
tor phosphorylation while at the same time increasing
expression of protein-tyrosine phosphatase 1B (PTP1B)
(41), a negative regulator of insulin receptor signaling
(44,45). Reports regarding the effects of leptin on compo-
nents of the insulin signaling pathway in hepatocytes also
differ considerably. For example, leptin has been reported
to alter insulin signaling by increasing association of p85
with insulin receptor substrate (IRS)-1 and decreasing
Lepr
flox/floxAlbcre tg-
Lepr
flox/floxAlbcre tg+
A
P=0.031
B
0.0
0.2
0.4
0.6
0.8
Lepr
flox/floxAlbcre
tg- tg- tg+ tg+
p-Akt
Total Akt
p-Akt/T
otal A
kt (arbitrary units
)
FIG. 7. Attenuation of hepatic leptin signaling results in increased
insulin-stimulated phosphorylation of Akt in the liver. Following the
hyperinsulinemic-euglycemic clamp, liver tissues were harvested and
ﬂash-frozen. Liver lysates were prepared and Western blots performed
for phosphorylated and total Akt levels. Representative blots from two
Lepr
ﬂox/ﬂox Albcre tg
 and two Lepr
ﬂox/ﬂox Albcre tg
 mice are shown in
A. Quantiﬁcation of all samples by densitometry is shown in B, n > 8.
Data are mean  SEM. p-Akt, phosphorylated Akt.
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increasing IRS-2 tyrosine phosphorylation and association
with p85 and decreasing IRS-1 tyrosine phosphorylation
(42). Other studies have found leptin to reduce insulin-
dependent IRS-1/IRS-2 association with p85 (40) while still
other studies ﬁnd that leptin is not able to modify the
effects of insulin on IRS-1/IRS-2 phosphorylation (45).
Thus, it appears there is a complex relationship between
leptin and its effects on hepatic insulin sensitivity and
signaling. Chronic versus acute actions of leptin may be
one factor dictating if leptin exerts pro- or anti-insulin
sensitizing effects on the liver. From our current work, we
have assessed the functional signiﬁcance of a chronic loss
of hepatic leptin activity and found that this leads ulti-
mately to increased hepatic insulin sensitivity.
It is interesting that a complete loss of leptin receptor
signaling (db/db mice) is associated with a worsening of
glucose homeostasis, whereas the loss of leptin action on
the liver appears to function in the opposite manner. This
observation suggests that leptin has divergent effects on
different tissues. While it has been shown that leptin can
act directly on the brain to cause a secondary increase in
insulin sensitivity in the liver (12,13), our study shows that
losing functional leptin receptors in the liver can also
increase hepatic insulin sensitivity. Thus, the present
study provides evidence that under certain conditions,
leptin action on hepatocytes may function to curtail and
control the extent of insulin action on the liver. This is
consistent with the action of leptin to limit insulin effects
in the periphery by directly suppressing insulin secretion
from pancreatic -cells (46–48) and decreasing lipid stor-
age in adipose tissue (49,50). It is possible that leptin plays
an important role in keeping insulin effects in check to
protect against hypoglycemia after postprandial insulin
release. This may explain why the most striking effects on
glucose metabolism that we saw as a result of ablated
hepatic leptin signaling occurred during the postprandial
state (Fig. 3) or during a state of hyperinsulinemia (Figs. 6
and 7) and not when insulin levels were low (supplemen-
tary Fig. 2). Therefore, leptin may differentially regulate
glucose metabolism by acting either on the brain or the
periphery, and the overall effect of leptin may depend on
the current metabolic state. Clearly, a complex relation-
ship exists between the effects of leptin on the brain and
the periphery, and a disruption of this relationship may
result in metabolic abnormalities such as diabetes and
obesity. Nonetheless, given the remarkable ability of a loss
of hepatic leptin signaling to protect against glucose
intolerance during aging and a high-fat diet, which are two
of the most prevalent risk factors for type 2 diabetes,
hepatic leptin signaling is a candidate therapeutic target
and further studies are warranted in this area.
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